| Literature DB >> 22406269 |
Fanny Chalmin1, Grégoire Mignot, Mélanie Bruchard, Angélique Chevriaux, Frédérique Végran, Aziz Hichami, Sylvain Ladoire, Valentin Derangère, Julie Vincent, David Masson, Simon C Robson, Gerard Eberl, Jean René Pallandre, Christophe Borg, Bernhard Ryffel, Lionel Apetoh, Cédric Rébé, Francois Ghiringhelli.
Abstract
Although Th17 cells are known to promote tissue inflammation and autoimmunity, their role during cancer progression remains elusive. Here, we showed that in vitro Th17 cells generated with the cytokines IL-6 and TGF-β expressed CD39 and CD73 ectonucleotidases, leading to adenosine release and the subsequent suppression of CD4(+) and CD8(+) T cell effector functions. The IL-6-mediated activation of the transcription factor Stat3 and the TGF-β-driven downregulation of Gfi-1 transcription factor were both essential for the expression of ectonucleotidases during Th17 cell differentiation. Stat3 supported whereas Gfi-1 repressed CD39 and CD73 expression by binding to their promoters. Accordingly, Th17 cells differentiated with IL-1β, IL-6, and IL-23 but without TGF-β did not express ectonucleotidases and were not immunosuppressive. Finally, adoptive transfer of Th17 cells induced by TGF-β and IL-6 promoted tumor growth in a CD39-dependent manner. Thus, ectonucleotidase expression supports the immunosuppressive fate of Th17 cells in cancer. Copyright ÂEntities:
Mesh:
Substances:
Year: 2012 PMID: 22406269 DOI: 10.1016/j.immuni.2011.12.019
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745